Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes

John F. Seymour, John M. Bennett, Alan F. List, Ghulam J. Mufti, Steven D. Gore, Pierre Fenaux, Valeria Santini, Joel Hetzer, Stephen Songer, Barry S. Skikne, Charles L. Beach

Research output: Contribution to journalArticle

Abstract

The efficacy and tolerance of azacitidine in higher-risk myelodysplasia with hypocellular bone marrow (BM) are unknown. This post hoc AZA-001 trial analysis assessed whether baseline BM cellularity affected the overall survival (OS) advantage demonstrated with azacitidine versus conventional care regimens (CCR). Baseline BM biopsies of

Original languageEnglish (US)
Pages (from-to)49-56
Number of pages8
JournalBritish Journal of Haematology
Volume165
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Azacitidine
Myelodysplastic Syndromes
Bone Marrow
Biopsy
Survival

Keywords

  • Azacitidine
  • Conventional care regimens
  • Hypocellular bone marrow
  • Myelodysplastic syndromes
  • Overall survival

ASJC Scopus subject areas

  • Hematology

Cite this

Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. / Seymour, John F.; Bennett, John M.; List, Alan F.; Mufti, Ghulam J.; Gore, Steven D.; Fenaux, Pierre; Santini, Valeria; Hetzer, Joel; Songer, Stephen; Skikne, Barry S.; Beach, Charles L.

In: British Journal of Haematology, Vol. 165, No. 1, 2014, p. 49-56.

Research output: Contribution to journalArticle

Seymour, JF, Bennett, JM, List, AF, Mufti, GJ, Gore, SD, Fenaux, P, Santini, V, Hetzer, J, Songer, S, Skikne, BS & Beach, CL 2014, 'Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes', British Journal of Haematology, vol. 165, no. 1, pp. 49-56. https://doi.org/10.1111/bjh.12723
Seymour, John F. ; Bennett, John M. ; List, Alan F. ; Mufti, Ghulam J. ; Gore, Steven D. ; Fenaux, Pierre ; Santini, Valeria ; Hetzer, Joel ; Songer, Stephen ; Skikne, Barry S. ; Beach, Charles L. / Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. In: British Journal of Haematology. 2014 ; Vol. 165, No. 1. pp. 49-56.
@article{34fe306a0d9148f490455cbce164144b,
title = "Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes",
abstract = "The efficacy and tolerance of azacitidine in higher-risk myelodysplasia with hypocellular bone marrow (BM) are unknown. This post hoc AZA-001 trial analysis assessed whether baseline BM cellularity affected the overall survival (OS) advantage demonstrated with azacitidine versus conventional care regimens (CCR). Baseline BM biopsies of",
keywords = "Azacitidine, Conventional care regimens, Hypocellular bone marrow, Myelodysplastic syndromes, Overall survival",
author = "Seymour, {John F.} and Bennett, {John M.} and List, {Alan F.} and Mufti, {Ghulam J.} and Gore, {Steven D.} and Pierre Fenaux and Valeria Santini and Joel Hetzer and Stephen Songer and Skikne, {Barry S.} and Beach, {Charles L.}",
year = "2014",
doi = "10.1111/bjh.12723",
language = "English (US)",
volume = "165",
pages = "49--56",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes

AU - Seymour, John F.

AU - Bennett, John M.

AU - List, Alan F.

AU - Mufti, Ghulam J.

AU - Gore, Steven D.

AU - Fenaux, Pierre

AU - Santini, Valeria

AU - Hetzer, Joel

AU - Songer, Stephen

AU - Skikne, Barry S.

AU - Beach, Charles L.

PY - 2014

Y1 - 2014

N2 - The efficacy and tolerance of azacitidine in higher-risk myelodysplasia with hypocellular bone marrow (BM) are unknown. This post hoc AZA-001 trial analysis assessed whether baseline BM cellularity affected the overall survival (OS) advantage demonstrated with azacitidine versus conventional care regimens (CCR). Baseline BM biopsies of

AB - The efficacy and tolerance of azacitidine in higher-risk myelodysplasia with hypocellular bone marrow (BM) are unknown. This post hoc AZA-001 trial analysis assessed whether baseline BM cellularity affected the overall survival (OS) advantage demonstrated with azacitidine versus conventional care regimens (CCR). Baseline BM biopsies of

KW - Azacitidine

KW - Conventional care regimens

KW - Hypocellular bone marrow

KW - Myelodysplastic syndromes

KW - Overall survival

UR - http://www.scopus.com/inward/record.url?scp=84896047476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896047476&partnerID=8YFLogxK

U2 - 10.1111/bjh.12723

DO - 10.1111/bjh.12723

M3 - Article

C2 - 24467613

AN - SCOPUS:84896047476

VL - 165

SP - 49

EP - 56

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -